Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Pablo Katz"'
Autor:
Louis Terriou, Maria Piggin, Pascale Burmester, Fengkui Zhang, Alan Finnegan, Persefoni Kritikou, Claudia Mighiu, Christian Buehrer, Pablo Katz, Selma Mode, Xenia Studera, Huong Trinh, Talha Munir
Publikováno v:
HemaSphere, Vol 7, p e3528996 (2023)
Externí odkaz:
https://doaj.org/article/ddbcc3f336334b7ba822d26eb3868d33
Autor:
Renzo Colombo, Federico Pellucchi, Lorenzo Rocchini, Carmen Maccagnano, Pablo Katz, Valeria Pegoraro
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 14, Iss 1, Pp 27-32 (2013)
BACKGROUND: Bladder cancer accounts for 5-10% of all cancers in Europe and up to 85% patients presents a noninvasive tumor, whose treatment of choice is the transurethral bladder resection (TURB) paired with adjuvant intravesical chemotherapy or immu
Externí odkaz:
https://doaj.org/article/a1a3dabc53ab471faec468e3724183a0
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 12, Iss 3, Pp 119-127 (2011)
Introduction: prophylaxis with granulocyte colony-stimulating factors (G-CSF) is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy. Objective
Externí odkaz:
https://doaj.org/article/b8f68190a654413db0588427420b51e1
Autor:
Katharina Versmold, Ferras Alashkar, Carina Raiser, Richard Ofori‐Asenso, Tao Xu, Yutong Liu, Pablo Katz, Aijing Shang, Alexander Röth
Publikováno v:
European Journal of Haematology.
Objective: Describe the real-world clinical profile of eculizumab-treated patients by characterizing their short- and long-term clinical and laboratory outcomes. Methods: This retrospective study used preexisting medical records of eculizumab-treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83683880ba3a906f88903fe2b38466e1
https://doi.org/10.1111/ejh.13970
https://doi.org/10.1111/ejh.13970
Autor:
Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, Vadim V. Ptushkin, Ana Marin-Niebla, Ramon García-Sanz, Steven Le Gouill, Anastasios Stathis, Alessia Bottos, Habib Hamidi, Pablo Katz, Thomas Perretti, Jenna C. Willis, Christian Buske
Publikováno v:
Leukemia & lymphoma
Leukemia & lymphoma, 2022, pp.1-12. ⟨10.1080/10428194.2021.2015765⟩
Leukemia & lymphoma, 2022, pp.1-12. ⟨10.1080/10428194.2021.2015765⟩
International audience; We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with relapsed/refractory mantle cell lymphoma (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba8f96d704415a7299eec0f3aafbe50
https://pubmed.ncbi.nlm.nih.gov/35045765
https://pubmed.ncbi.nlm.nih.gov/35045765
Autor:
Pablo Katz, Carina Raiser, Alexander Roeth, Richard Ofori-Asenso, Katharina Versmold, Yutong Liu, Aijing Shang, Tao Xu, Ferras Alashkar
Background: Eculizumab, an anti-C5 antibody, was approved for the treatment of patients (pts) with symptomatic paroxysmal nocturnal hemoglobinuria (PNH) in 2007 and has been the standard of care for over a decade. However, published data on real-worl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b97d57a460cf2879b7d69e8f4f38f66
Publikováno v:
Current Medical Research and Opinion. 33:1481-1489
To identify characteristics, resource utilization, and safety profile of patients prescribed with lidocaine 5% medicated plaster, pregabalin, gabapentin, amitriptyline and duloxetine when experiencing pain in the real-world setting of general practit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9ca34927e51f6ff89b822c43b986c7
https://doi.org/10.1080/03007995.2017.1335191
https://doi.org/10.1080/03007995.2017.1335191
Publikováno v:
Current Medical Research and Opinion. 33:911-918
To evaluate the relative clinical efficacy, safety, and tolerability associated with two non-invasive patient-controlled analgesia (PCA) treatments, sufentanil sublingual tablet system (SSTS) and fentanyl iontophoretic patient-controlled transdermal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9c141fd49617dedaa361e1ec00fd8c0
https://doi.org/10.1080/03007995.2017.1294560
https://doi.org/10.1080/03007995.2017.1294560
Publikováno v:
Blood. 136:26-27
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease associated with major complications such as thrombotic events and impaired renal function. Prior to the introduction of C5 inhibitors in 2007, PNH had been fatal in about 35% of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99259e726d1dec17b40d8b4c025fc8b1
https://doi.org/10.1182/blood-2020-140679
https://doi.org/10.1182/blood-2020-140679
Publikováno v:
Blood. 136:31-32
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a life-threatening disease of dysregulated complement activation characterized by hemolysis and thrombosis and is associated with bone marrow failure. PNH can also impair patient quality of life
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f72f49e42af90588a403478e25c6e24
https://doi.org/10.1182/blood-2020-137454
https://doi.org/10.1182/blood-2020-137454